The IL-23 inhibitor from AbbVie indicated for the treatment of moderately to severely active Crohn's disease (CD) in adults.¹

RESOURCES
FOR YOUR PATIENTS
AND YOUR PRACTICE

PARK TALK SERIES: VIDEO LIBRARY

ENDOSCOPIC OUTCOMES IN CD

Dr. Casey Chapman, Dr. Bincy Abraham, and Dr. Anita Afzali describe SKYRIZI's Phase 3 clinical trial results. SKYRIZI is the first approved product in Crohn's disease with co-primary endpoints aligned to STRIDE-II recommendations.

Transcript

CLINICAL OUTCOMES IN CD

Dr. Casey Chapman, Dr. Asher Kornbluth, and Dr. Jennifer Seminerio present SKYRIZI induction trial results at Weeks 4 and 12, and maintenance trial results at Week 52.

Transcript

DOSING AND ADMINISTRATION WITH OBI

Dr. Casey Chapman, Dr. Amar Naik, Dr. Asher Kornbluth, and Dr. Jennifer Seminerio explain SKYRIZI dosing and how the SKYRIZI on-body injector can offer patients flexibility in administering their maintenance treatment at home or in office.

Transcript

OBI=on-body injector

SUPPORT FOR YOUR OFFICE

YOUR SOURCE FOR SUPPORT TO GET PATIENTS TIMELY ACCESS TO SKYRIZI

SKYRIZI COMPLETE ENROLLMENT

Ready to enroll your patient in Skyrizi Complete and start the process?

Get Started

BILLING AND CODING

Clear guidance on billing and coding for SKYRIZI, including NDC codes.

Get Started

ACCESS AND REIMBURSEMENT

Forms and instructions to help patients with access and coverage.

Get Started

Specialty Pharmacies and Distributors

Contact details for specialty pharmacies, wholesalers and specialty distributors.

Get Started

This information is for informational purposes only and is not intended to provide reimbursement or legal advice. The information presented here does not guarantee payment or coverage.

SKYRIZI COMPLETE ENROLLMENT

SKYRIZI COMPLETE ENROLLMENT AND PRESCRIPTION FORM

Download and fill out the Skyrizi Complete Enrollment and Prescription Form with your patient.
After submitting the form, your patient will receive a call from a Nurse Ambassador* within one business day. The call may come from any area code.

Download

*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

PRIOR AUTHORIZATION INSTRUCTIONS

Follow this helpful checklist to request coverage of SKYRIZI.

Download

BILLING AND CODING

GUIDE TO BILLING AND CODING

Your guide to relevant codes (including commercial and Medicare) as well as helpful tips for completing forms.

Download

NDC CODES

Single-dose Vial
600 mg/10.0 mL

0‍0‍7‍4‍-‍5‍0‍1‍5‍-‍0‍1
Carton of 1

Single-dose Prefilled Cartridge
With On-Body Injector (OBI) 180 mg/1.2 mL

007‍4-1‍065‍-0‍1
Kit

Single-dose Prefilled Cartridge
With On-Body Injector (OBI) 360 mg/2.4 mL

0‍0‍7‍4‍-‍1‍0‍7‍0‍-‍0‍1
Kit

ACCESS AND REIMBURSEMENT FORMS

Along with support from Skyrizi Complete, you can use the forms here to help patients with access and coverage for SKYRIZI.

APPEALS LETTER SAMPLE

Appeal a denied claim for SKYRIZI.

Appeal Letter Instructions

Download

FORMULARY EXCEPTION LETTER

Request a formulary exception to allow coverage for SKYRIZI.

Formulary Exception Letter Instructions

Download

HIPAA AUTHORIZATION

Allow patients to authorize the release of health information related to their treatment with SKYRIZI.

Download

LETTER OF MEDICAL NECESSITY

Establish the medical necessity of SKYRIZI.

Letter of Medical Necessity Instructions

Download

TIERED EXCEPTION LETTER

Request lower cost sharing for SKYRIZI as a preferred medication.

Tiered Exception Letter Instructions

Download

ASSIST PATIENTS WITH SKYRIZI IV & ADMINISTRATION COSTS

Utilize this form as a guide when submitting patient claims for reimbursement, for eligible, commercially insured patients using the Skyrizi Complete Savings Card.

Download

FOR SUPPORT IN PERSON OR OVER THE PHONE, CALL YOUR ACCESS SPECIALIST AT 1.877.COMPLETE (1.877.266.7538)

SPECIALTY PHARMACIES AND DISTRIBUTORS

SPECIALTY PHARMACIES

A complete list of specialty pharmacies that provide On-Body Injector (OBI) support for SKYRIZI.

Download

WHOLESALERS AND SPECIALTY DISTRIBUTORS

A complete list of wholesalers and specialty distributors that provide IV infusion support for SKYRIZI.

Download

LOOKING FOR MORE RESOURCES?

Streamline the Rx process for patients with CompletePro.com. You can help patients by:

Digitally enrolling patients into Skyrizi Complete, giving them access to important resources like a Nurse Ambassador*
Requesting medical and/or pharmacy benefit verifications and completing the prior authorization
Sending prescriptions to the patient’s specialty pharmacy of choice with the option of including a savings card (if eligible)

Receiving alerts when a prior authorization is going to expire and be informed of insurance changes in the new year
Using the Reimbursement Portal to submit, manage, and view claims for patient reimbursement for infused patients
Tracking where patients are in the prescription process

*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing health care professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

INFORMATION FOR PATIENTS

USE THESE GUIDES AND BEST PRACTICES TO HELP GET PATIENTS TIMELY ACCESS TO SKYRIZI

SKYRIZI COMPLETE ENROLLMENT

Get Started

TREATMENT VIDEOS

Get Started

ADDITIONAL RESOURCES

Get Started

The resources on this page are provided for informational purposes only and are not intended as reimbursement or legal advice. The information presented here does not guarantee payment or coverage.

SKYRIZI COMPLETE ENROLLMENT

SKYRIZI COMPLETE ENROLLMENT AND PRESCRIPTION FORM

Download and fill out the Skyrizi Complete Enrollment and Prescription Form with your patient.
After submitting the form, your patient will receive a call from a Nurse Ambassador* within one business day. The call may come from any area code.

Download

TREATMENT VIDEOS

Introduction to Infusion

A video guiding patients on how to prepare for their SKYRIZI infusion.

Transcript

Injection Training

A video guiding patients on how to inject SKYRIZI using the On-Body Injector (OBI).

Transcript

ADDITIONAL RESOURCES

Benefits Verification Checklist

Helps patients confirm their insurance coverage and out-of-pocket costs.

Download

INSURANCE COMPARISON

Simple steps to help patients choose their insurance coverage when it's time to pick a plan.

Download

PATIENT BROCHURE

Provides patients with an overview of how SKYRIZI works, including key efficacy, safety, and dosing information.

Download

STAY UP TO DATE ON THE LATEST
SKYRIZI NEWS AND INFORMATION

ENROLL PATIENTS IN
SKYRIZI COMPLETE

ENROLL NOW

	ADVANCE N=850
CO-PRIMARY ENDPOINTS	Endoscopic Response^a (>50% decrease in SES-CD) and Clinical Remission^b (CDAI <150) at Week 12
DURATION	12-week, randomized, double-blind, placebo-controlled, multi-center study
CONCOMITANT THERAPIES	All patients may have received concomitant conventional therapies that included 5-aminosalicylates, immunomodulators, corticosteroids, and Crohn's-related antibiotics
DOSING	IV infusion of SKYRIZI 600 mg, risankizumab-rzaa 1200 mg^c or placebo, at Weeks 0, 4, and 8
INCLUSION CRITERIA	Moderately to severely active CD: CDAI 220-450 Average daily SF ≥4 or APS ≥2 SES-CD ≥6 (≥4 for isolated ileitis), exluding the narrowing component 16-80 years old Bio-naïve^d or biologic failure^e

	MOTIVATE N=569
CO-PRIMARY ENDPOINTS	Endoscopic Response^a (>50% decrease in SES-CD) and Clinical Remission^b (CDAI <150) at Week 12
DURATION	12-week, randomized, double-blind, placebo-controlled, multi-center study
CONCOMITANT THERAPIES	All patients may have received concomitant conventional therapies that included 5-aminosalicylates, immunomodulators, corticosteroids, and Crohn's-related antibiotics
DOSING	IV infusion of SKYRIZI 600 mg, risankizumab-rzaa 1200 mg^c or placebo, at Weeks 0, 4, and 8
INCLUSION CRITERIA	Moderately to severely active CD: CDAI 220-450 Average daily SF ≥4 or APS ≥2 SES-CD ≥6 (≥4 for isolated ileitis), exluding the narrowing component 16-80 years old Biologic failure^e

	FORTIFY N=382
CO-PRIMARY ENDPOINTS	Endoscopic Response^a (>50% decrease in SES-CD) and Clinical Remission^b (CDAI <150) at Week 52
DURATION	52-week, randomized, double-blind, placebo-controlled, multi-center study
CONCOMITANT THERAPIES	All patients may have received concomitant conventional therapies that included 5-aminosalicylates, immunomodulators, and Crohn's-related antibiotics Patients taking corticosteroids at the start of FORTIFY had their therapy tapered
DOSING	Subcutaneous injection of SKYRIZI 180 mg, SKYRIZI 360 mg or placebo starting at Week 12 and every 8 weeks after
INCLUSION CRITERIA	Moderately to severely active CD: Entry and completion of ADVANCE or MOTIVATE. Completion includes the final endoscopy of ADVANCE or MOTIVATE Achieved Clinical Response^f in ADVANCE or MOTIVATE studies

FORTIFY		Placebo (Induction Responder) N=130	SKYRIZI 180 mg SC N=135	SKYRIZI 360 mg SC N=117
BASELINE OF INDUCTION (ADVANCE, MOTIVATE)
	Male, n (%)	72 (55.4)	62 (45.9)	67 (57.3)
	Age (years), mean (SD)	38.0 (12.8)	39.2 (14.7)	36.2 (12.6)
	Disease duration (years), mean (SD)	9.6 (8.2)	10.6 (10.2)	8.6 (7.1)
	Disease Location
	lleal only, n (%)	18 (14)	12 (9)	13 (11)
	Colonic only, n (%)	49 (38)	63 (47)	52 (44)
	lleal-colonic, n (%)	63 (49)	60 (44)	52 (44)
	Baseline immunomodulatorimmuno- modulator use, n (%)	33 (25.4)	37 (27.4)	34 (29.1)
	Baseline steroid use, n (%)	40 (30.8)	47 (34.8)	36 (30.8)
	Biologics failure history
	0, n (%)	31 (23.8)	40 (29.6)	34 (29.1)
	1, n (%)	49 (37.7)	34 (25.2)	42 (35.9)
	>1, n (%)	50 (38.5)	61 (45.2)	41 (35.0)
	Baseline CDAI, mean (SD)	314.2 (64.2)	327.6 (68.2)	316.2 (59.6)
	Baseline SES-CD, mean (SD)	14.1 (7.1)	14.9 (7.2)	14.3 (7.0)
	Baseline SF, mean (SD)	5.8 (2.7)	6.2 (3.1)	5.9 (2.7)
	Baseline APS, mean (SD)	1.9 (0.5)	2.0 (0.4)	1.9 (0.5)
	Baseline FCP (mg/kg), median (min,max)	904.0 (30, 11378)	1666.0 (30, 28800)	1622.0 (30, 14649)
	Baseline hs-CRP (mg/L), median (min,max)	7.9 (0.3, 181)	8.7 (0.4, 151)	10.6 (0.3, 129)

Week 0 of Maintenance
	CDAI at Week 0, mean (SD)	111.6 (69.5)	117.6 (66.8)	125.4 (62.7)
	SES-CD at Week 0, mean (SD)	7.9 (6.4)	7.8 (6.4)	8.3 (7.3)
	SF at Week 0, mean (SD)	1.4 (1.7)	2.1 (1.9)	1.9 (1.7)
	APS at Week 0, mean (SD)	0.6 (0.5)	0.6 (0.5)	0.6 (0.5)
	FCP at Week 0 (mg/kg), median (min,max)	300.0 (30, 22912)	361 (30, 28800)	485.5 (30, 14804)
	hs-CRP at Week 0 (mg/L), median (min,max)	3.6 (0, 42)	3.7 (0, 48)	4.0 (0, 258)

RESOURCES
FOR YOUR PATIENTS
AND YOUR PRACTICE

PARK TALK SERIES: VIDEO LIBRARY

YOUR SOURCE FOR SUPPORT TO GET PATIENTS TIMELY ACCESS TO SKYRIZI

SKYRIZI COMPLETE ENROLLMENT

BILLING AND CODING

ACCESS AND REIMBURSEMENT FORMS

SPECIALTY PHARMACIES AND DISTRIBUTORS

LOOKING FOR MORE RESOURCES?

USE THESE GUIDES AND BEST PRACTICES TO HELP GET PATIENTS TIMELY ACCESS TO SKYRIZI

SKYRIZI COMPLETE ENROLLMENT

TREATMENT VIDEOS

ADDITIONAL RESOURCES

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

largest phase 3 clinical program in crohn's disease TO DATE ACROSS INDICATION APPROVAL TRIALS*

largest phase 3 clinical program in crohn's disease TO DATE ACROSS INDICATION APPROVAL TRIALS*
1,419 PATIENTS ENROLLED ACROSS SKYRIZI TRIALS

Phase 3 Clinical program: Study Design Details^1-5

ADVANCE
N=850

MOTIVATE
N=569

FORTIFY
N=382

Phase 3 clinical program: baseline characteristics^1,2

ADVANCE

Placebo
N=175

SKYRIZI 600 mg IV
N=336

MOTIVATE

Placebo
N=187

SKYRIZI 600 mg IV
N=191

FORTIFY

Placebo
(Induction Responder)
N=130

SKYRIZI
180 mg SC
N=135

SKYRIZI
360 mg SC
N=117

FORTIFY

Placebo (Induction Responder)
N=164

SKYRIZI 360mg SC
N=141

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

RESOURCES FOR YOUR PATIENTS AND YOUR PRACTICE

PARK TALK SERIES: VIDEO LIBRARY

YOUR SOURCE FOR SUPPORT TO GET PATIENTS TIMELY ACCESS TO SKYRIZI

SKYRIZI COMPLETE ENROLLMENT

BILLING AND CODING

ACCESS AND REIMBURSEMENT FORMS

SPECIALTY PHARMACIES AND DISTRIBUTORS

LOOKING FOR MORE RESOURCES?

USE THESE GUIDES AND BEST PRACTICES TO HELP GET PATIENTS TIMELY ACCESS TO SKYRIZI

SKYRIZI COMPLETE ENROLLMENT

TREATMENT VIDEOS

ADDITIONAL RESOURCES

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

ADVANCE N=850

MOTIVATE N=569

FORTIFY N=382

ADVANCE

Placebo N=175

SKYRIZI 600 mg IV N=336

MOTIVATE

Placebo N=187

SKYRIZI 600 mg IV N=191

FORTIFY

Placebo (Induction Responder) N=130

SKYRIZI 180 mg SC N=135

SKYRIZI 360 mg SC N=117

FORTIFY

Placebo (Induction Responder) N=164

SKYRIZI 360mg SC N=141

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

RESOURCES
FOR YOUR PATIENTS
AND YOUR PRACTICE

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

ADVANCE
N=850

MOTIVATE
N=569

FORTIFY
N=382

Placebo
N=175

SKYRIZI 600 mg IV
N=336

Placebo
N=187

SKYRIZI 600 mg IV
N=191

Placebo
(Induction Responder)
N=130

SKYRIZI
180 mg SC
N=135

SKYRIZI
360 mg SC
N=117

Placebo (Induction Responder)
N=164

SKYRIZI 360mg SC
N=141

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹